Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inh...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

dcrown May. 12 at 4:58 PM

$IMRX The latest corporate update from Immuneering confirms that they have advanced beyond the initial 34-patient group and are preparing a massive data presentation for next month. As of today (May 12, 2026), median overall survival (mOS) has still not been officially reached

0 · Reply

dcrown May. 12 at 4:53 PM

$IMRX jeez what’s happening

0 · Reply

watchaddict May. 12 at 4:24 PM

$IMRX 1000 whole sector down load up

0 · Reply

Dognat May. 12 at 3:26 PM

$IMRX Just like Watchaddict says, Adding 😁 Excited about these pricing going into the June 1st data release at ASCO, arguably the largest and most prestigious cancer conference

0 · Reply

playtrades2day May. 11 at 9:19 PM

$IMRX wake up!!!

0 · Reply

JuggernautRaider May. 10 at 8:52 PM

$IMRX earnings coming monday 🤫 i tried to get @Duediligence20 to sell $PPBT and buy this when it was below a $1.25 last year; Tony is a friend but now I realize I should have had just bought more 😜 $RVMD better watch their ass 🚽 Immuneering is coming 🚊

2 · Reply

BinaryLogic May. 9 at 11:02 AM

$MIST $RCKT $ABCL $OBIO $IMRX [Again] Investors are heavy in semi-conductors, AI/HPC and O&G related stocks presently which has created opportunities in-particular in biotechnology, small and large cap alike (IMO). That is not to suggest that major reversals here are imminent, but the setups are becoming increasingly opportunistic (IMO) intermediate term. UNCY COCH JSPR SCNX RANI TRAW NVAX MDT BSX

0 · Reply

dcrown May. 8 at 6:10 PM

$IMRX Immuneering (IMRX) is estimated to report its Q1 2026 earnings on Monday, May 11, 2026

1 · Reply

JuggernautRaider May. 8 at 6:10 PM

$IMRX 🐂 https://ir.immuneering.com/news-releases/news-release-details/immuneering-present-new-survival-data-first-line-pancreatic

0 · Reply

rickahuna May. 8 at 4:56 PM

$IMRX Recruiting Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (MAPKeeper 301) ClinicalTrials.gov ID NCT07562152 Sponsor Immuneering Corporation Last Update Posted 2026-05-06 Arizona Locations Phoenix, Arizona, United States, 85338 RecruitingCity of Hope Contact : Khaled Abouelezz, MD [email protected] California Locations Duarte, California, United States, 91010 RecruitingCity of Hope Contact : Vincent Chung, MD Illinois Locations Chicago, Illinois, United States, 60099 RecruitingCity of Hope Contact : Evan Pisick, MD New York Locations New York, New York, United States, 10016 RecruitingNYU Langone Health Contact : Study Team [email protected] Ohio Locations Maumee, Ohio, United States, 43537 RecruitingTaylor Cancer Research Center Contact : Stephanie Ambrose [email protected] Tennessee Locations Sarah Cannon Research Institute Contact : Meredith Pelster, MD [email protected]

0 · Reply

Immuneering announces updated data from Phase 2a trial for atebimetinib

Apr 21, 2026, 4:05 PM EDT - 21 days ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

2026-04-20T14:04:20.000Z - 23 days ago

Immuneering announces presentation of new genetic data at 2026 AACR

Apr 20, 2026, 9:00 AM EDT - 23 days ago

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Apr 13, 2026, 3:45 PM EDT - 4 weeks ago

Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:05 PM EDT - 5 weeks ago

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 17, 2026, 4:35 PM EDT - 2 months ago

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 9, 2026, 3:40 PM EDT - 2 months ago

Immuneering Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T10:56:34.000Z - 2 months ago

Immuneering price target lowered to $12 from $13 at Piper Sandler

2026-03-06T12:52:29.000Z - 2 months ago

Immuneering reports Q4 EPS (18), consensus (31c)

2026-03-06T12:52:10.000Z - 2 months ago

Immuneering sees cash runway into 2029

Mar 6, 2026, 7:45 AM EST - 2 months ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 2 months ago

Immuneering to Present at the Leerink Global Healthcare Conference

Feb 26, 2026, 10:00 AM EST - 2 months ago

Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 4:05 PM EST - 2 months ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-08T17:55:15.000Z - 4 months ago

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

RVMD

2026-01-07T23:45:14.000Z - 4 months ago

Immuneering reports ‘positive’ survival, safety data from atebimetinib trial

Jan 7, 2026, 4:30 PM EST - 4 months ago

Immuneering Transcript: Study Result

Jan 7, 2026, 4:00 PM EST - 4 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

2026-01-07T19:25:26.000Z - 4 months ago

Immuneering management to meet with Oppenheimer

2025-12-23T13:11:36.000Z - 5 months ago

Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP

Dec 23, 2025, 8:00 AM EST - 5 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

2025-12-17T21:20:40.000Z - 5 months ago

Immuneering on track to dose first patient in pancreatic cancer trial in 2026

Dec 17, 2025, 4:05 PM EST - 5 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

2025-12-16T13:10:41.000Z - 5 months ago

Immuneering to be added to the Nasdaq Biotechnology Index

Dec 16, 2025, 8:00 AM EST - 5 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 4, 2025, 11:10 AM EST - 5 months ago

Immuneering Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 6 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

2025-11-12T21:30:52.000Z - 6 months ago

Immuneering reports Q3 EPS (38c), consensus (39c)

2025-11-12T21:30:41.000Z - 6 months ago

Immuneering expects cash to fund operations into 2029

Nov 12, 2025, 4:30 PM EST - 6 months ago

Immuneering Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 6 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 26, 2025, 4:01 PM EDT - 8 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 12:08 AM EDT - 8 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 8 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 8 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 8 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 8 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Aug 26, 2025, 4:05 PM EDT - 9 months ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 9 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 9 months ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Immuneering Transcript: Study Update

Jun 17, 2025, 6:00 AM EDT - 11 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Immuneering Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 9, 2025, 1:30 PM EDT - 1 year ago

Immuneering Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 12, 2025, 2:40 PM EST - 1 year ago

Immuneering Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Transcript: Study Result

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 5, 2024, 1:00 PM EST - 1 year ago

Immuneering Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:30 PM EDT - 1 year ago

Immuneering Transcript: Study Update

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 6, 2024, 10:00 AM EDT - 1 year ago

Immuneering Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jun 5, 2024, 4:30 PM EDT - 2 years ago

Immuneering Transcript: Jefferies 2024 Global Healthcare Conference

May 7, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 2 years ago

Immuneering Recognizes Melanoma Awareness Month

Apr 11, 2024, 3:00 PM EDT - 2 years ago

Immuneering Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 2 years ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Immuneering Transcript: Study Result

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

dcrown May. 12 at 4:58 PM

0 · Reply

dcrown May. 12 at 4:53 PM

$IMRX jeez what’s happening

0 · Reply

watchaddict May. 12 at 4:24 PM

$IMRX 1000 whole sector down load up

0 · Reply

Dognat May. 12 at 3:26 PM

$IMRX Just like Watchaddict says, Adding 😁 Excited about these pricing going into the June 1st data release at ASCO, arguably the largest and most prestigious cancer conference

0 · Reply

playtrades2day May. 11 at 9:19 PM

$IMRX wake up!!!

0 · Reply

JuggernautRaider May. 10 at 8:52 PM

2 · Reply

BinaryLogic May. 9 at 11:02 AM

0 · Reply

dcrown May. 8 at 6:10 PM

$IMRX Immuneering (IMRX) is estimated to report its Q1 2026 earnings on Monday, May 11, 2026

1 · Reply

JuggernautRaider May. 8 at 6:10 PM

$IMRX 🐂 https://ir.immuneering.com/news-releases/news-release-details/immuneering-present-new-survival-data-first-line-pancreatic

0 · Reply

rickahuna May. 8 at 4:56 PM

0 · Reply

RagingGreg May. 7 at 8:57 PM

$IMRX when do you guys think this company would be bought out?

1 · Reply

_JAKE May. 7 at 6:52 PM

$IMRX The Phase 3 MAPKeeper 301 study tests Immuneering Corp.’s drug atebimetinib with a modified gemcitabine and nab-paclitaxel combo as first line therapy for metastatic pancreatic cancer. The official goal is to see if adding this oral drug to standard chemo improves outcomes versus standard treatment alone, a key question in a high-need cancer segment. This is an interventional Phase 3 study with patients randomly assigned to one of the two treatment arms. The study was first submitted in April 2026, marking the formal launch of the Phase 3 program for atebimetinib in this cancer setting. The most recent update came on May 5, 2026, showing that the trial is active and recruiting, which matters for tracking timelines to key efficacy readouts. For IMRX, a successful outcome could shift expectations on long term revenue potential and support a higher valuation as the drug moves closer to possible approval.

1 · Reply

D541 May. 7 at 5:08 PM

$IMRX

0 · Reply

rickahuna May. 7 at 2:10 PM

$IMRX Atebimetinib should be getting more news coverage mOS not yet reached (NR) mPFS not yet reached (NR)

0 · Reply

watchaddict May. 7 at 12:53 PM

$IMRX adding LFG

0 · Reply

Quantumup May. 7 at 12:06 PM

Needham⬇️ $RVMD's PT to $183 (was $186), reiterated at Buy, and said: The 1Q26 EPS of -$2.29 came in lower than cons. of -$1.64, driven by higher than expected SG&A (-$46.3M var) and R&D (-$67.4M var). $IMRX $ERAS BBOT TGNX ANL VSTM Needham added—This was attributed to an update in the company's equity compensation program that resulted in an increase in the stock-based compensation (+$44.6M) which also increased the full year 2026 stock-based expense to be between $260 - 280M (~+$80M) and FY 2026 GAAP to be $1.7-1.8B (previously $1.6-1.7B). The other new update this quarter was an increase in the enrollment number for RASolute 301 (Dara in 2L NSCLC) from 420 to 590 patients to increase the powering on OS (dual PE), although this does not change the timing of the study with enrollment substantially expected to complete in 2026. We update our model for the quarter and for the new OPEX guidance, which lowers our PT slightly to $183. Reiterate Buy.

0 · Reply

dcrown May. 6 at 7:50 PM

$IMRX jeez what happens , adding here

0 · Reply

Eruption May. 6 at 4:14 PM

$IMRX More BS manipulation. Utter garbage.

1 · Reply

OfficialStocktwitsUser May. 6 at 3:14 PM

$IMRX RSI: 42.74, MACD: -0.0030 Vol: 0.26, MA20: 5.56, MA50: 5.33 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

rickahuna May. 5 at 11:37 PM

$IMRX Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager So PFE, maybe look at IMRX's atebi to complement Ponsegromab and you won't have a failure.

0 · Reply

rickahuna May. 5 at 3:05 PM

$IMRX 1. Vote Board of Directors: More Details Vote Directors Individually showing combined election of directors, radio button options Election of Director: Peter Feinberg Election of Director: Laurie B. Keating Interesting nominees; a venture capitalist and biotech lawyer

0 · Reply

watchaddict May. 5 at 1:51 PM

$IMRX 1000 more lfg

0 · Reply

Market Cap	336.42M
Revenue (ttm)	0.00
Net Income (ttm)	-56.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	536,700
Avg Vol	914,450
Day's Range	N/A - N/A
Shares Out	64.70M
Stochastic %K	30%
Beta	0.37
Analysts	Strong Sell
Price Target	$17.00